AcelRx mit FDA Ende Juli? - 500 Beiträge pro Seite
eröffnet am 21.07.14 00:12:22 von
neuester Beitrag 25.02.16 14:35:36 von
neuester Beitrag 25.02.16 14:35:36 von
Beiträge: 17
ID: 1.196.576
ID: 1.196.576
Aufrufe heute: 0
Gesamt: 2.559
Gesamt: 2.559
Aktive User: 0
ISIN: US00444T2096 · WKN: A3DWPN · Symbol: TLPH
0,9594
USD
+2,06 %
+0,0194 USD
Letzter Kurs 02:00:00 NYSE
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +25,00 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 | |
| 1,0900 | +14,74 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5058 | -12,79 | |
| 0,8410 | -17,06 | |
| 9,7200 | -19,60 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Feedback
Ein in DE fast unbekannter Player aus dem Bereich Pain Management.
Um was geht es?
http://www.acelrx.com/pipeline/arx-01.html
Warum interessant?
Der naechste Katalysator steht unmittelbar vor der Tür (PDUFA Date: 27. Juli) was der Aktie einen guten Schub geben koennte.
Aktuelle News:
- "We See A Buying Opportunity One Week Before Zalviso PDUFA" Says Roth Capital http://www.smarteranalyst.com/2014/07/18/acelrx-we-see-a-buy…
- "Unless something goes horribly wrong, AcelRx Pharmaceuticals (ACRX_) should win FDA approval for the Zalviso pain-killing device on July 27." AF Biotech Stock Mailbag http://www.thestreet.com/story/12775982/1/biotech-stock-mail…
- "AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month" http://seekingalpha.com/article/2296285-acelrx-should-trend-…
Warum ich die Aktie gut finde:
Auf dem aktuellen Niveau ein gutes Chance/Risiko Verhaeltnis. Feuerstein & Co. geben der Aktie zusaetzlichen Drive.
Ansonsten:
Shorts beachten http://shortsqueeze.com/?symbol=acrx&submit=Short+Quote%99 und SL entsprechend setzen.
Meinungen hierzu?
Neuer SA Artikel:
"If any price multiple is applied to the stock, it's easy to see why some analysts have a 1 year price target exceeding $20."
http://seekingalpha.com/article/2332555-shorting-acelrx-into…
Mal sehn was heute geht....
"If any price multiple is applied to the stock, it's easy to see why some analysts have a 1 year price target exceeding $20."
http://seekingalpha.com/article/2332555-shorting-acelrx-into…
Mal sehn was heute geht....
Gestern gab es nachboerslich eine Aenderung an ACRX Website mit der Meldung das "Zalvisio" von der FDA "approved" wurde (Screenshot unter https://twitter.com/BioBreakout/status/492448788712550400).
Die Meldung is relativ schnell wieder verschwunden und ACRX hat dementiert: "The company recently learned that a rumor circulated online stating the Food and Drug Administration (FDA) had approved Zalviso. As of July 24, 2014 there has been no notification to the company from the FDA regarding the status of the Zalviso New Drug Application (NDA)." http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-acelrxn…
AH stieg die Aktie um knapp 6% auf $10.80.
Die Meldung is relativ schnell wieder verschwunden und ACRX hat dementiert: "The company recently learned that a rumor circulated online stating the Food and Drug Administration (FDA) had approved Zalviso. As of July 24, 2014 there has been no notification to the company from the FDA regarding the status of the Zalviso New Drug Application (NDA)." http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-acelrxn…
AH stieg die Aktie um knapp 6% auf $10.80.
Why AcelRx Pharmaceuticals Inc Stock Boomed
What: Shares of AcelRx Pharmaceuticals (NASDAQ: ACRX ) , a health care company developing the Zalviso pain-managing drug delivery system, jumped by as much as 11% today after the company confirmed its July 27 PDUFA date for Zalviso with the FDA.
So what: According to the company's press release, rumors had swirled that regulators already had approved the device -- but so far, AcelRx noted that it hasn't heard an answer over its regulatory filing for Zalviso. Investors, however, have rallied around the stock as analysts grow optimistic over an FDA approval for Zalviso. Piper Jaffrey noted last month that it expects a "timely approval" of the device around its PDUFA date, particularly after Zalviso posted strong safety and efficacy data in earlier clinical trials.
Now what: Signs are looking good for Zalviso's approval moving forward, and today's stock jump points to investor confidence in just that outcome. There's a sizable opportunity here for AcelRx: The company's drug delivery and pain-management system is aiming to compete with traditional IV-delivered pain control in hospitals, a practice AcelRx notes can lead to infections, human errors, and other potential hazards.
Zalviso has already won its share of supporters. AcelRx inked a deal worth up to $250 million to sell the system's European and Australian rights to German company Grunenthal GmbH, and Piper Jaffray foresees up to $300 million to $400 million in peak U.S. sales for the system if approved.
via http://www.fool.com/investing/general/2014/07/25/why-acelrx-…
What: Shares of AcelRx Pharmaceuticals (NASDAQ: ACRX ) , a health care company developing the Zalviso pain-managing drug delivery system, jumped by as much as 11% today after the company confirmed its July 27 PDUFA date for Zalviso with the FDA.
So what: According to the company's press release, rumors had swirled that regulators already had approved the device -- but so far, AcelRx noted that it hasn't heard an answer over its regulatory filing for Zalviso. Investors, however, have rallied around the stock as analysts grow optimistic over an FDA approval for Zalviso. Piper Jaffrey noted last month that it expects a "timely approval" of the device around its PDUFA date, particularly after Zalviso posted strong safety and efficacy data in earlier clinical trials.
Now what: Signs are looking good for Zalviso's approval moving forward, and today's stock jump points to investor confidence in just that outcome. There's a sizable opportunity here for AcelRx: The company's drug delivery and pain-management system is aiming to compete with traditional IV-delivered pain control in hospitals, a practice AcelRx notes can lead to infections, human errors, and other potential hazards.
Zalviso has already won its share of supporters. AcelRx inked a deal worth up to $250 million to sell the system's European and Australian rights to German company Grunenthal GmbH, and Piper Jaffray foresees up to $300 million to $400 million in peak U.S. sales for the system if approved.
via http://www.fool.com/investing/general/2014/07/25/why-acelrx-…
Trading Spotlight
Antwort auf Beitrag Nr.: 47.377.058 von Serafim201 am 26.07.14 00:10:04Here's why
http://www.finanznachrichten.de/nachrichten-2014-07/30952891…
http://www.finanznachrichten.de/nachrichten-2014-07/30952891…
Leider, leider, leider ein CRL und kein Approval.
http://finance.yahoo.com/news/acelrx-pharmaceuticals-receive…
Kommentar auf SA:
http://seekingalpha.com/article/2346275-zalviso-the-good-the…
Aktuell laeuft gerade ein Conference Call:
http://acelrx.equisolvewebcast.com/q2-2014
Moeglicherweise in den naechsten Tagen/Wochen ein gute Einstiegsmoeglichkeit.
http://finance.yahoo.com/news/acelrx-pharmaceuticals-receive…
Kommentar auf SA:
http://seekingalpha.com/article/2346275-zalviso-the-good-the…
Aktuell laeuft gerade ein Conference Call:
http://acelrx.equisolvewebcast.com/q2-2014
Moeglicherweise in den naechsten Tagen/Wochen ein gute Einstiegsmoeglichkeit.
Für den Risikobewussten Anleger mit Sitzfleisch gibt es die naechsten Tagen/Wochen ein gute Einstiegsmoeglichkeit.
Die Aktie ist gestern um 41% auf bis $6.11 eingebrochen. Der Markt hat hier aber mMn ueberreagiert. Die im cc genannten und von der SEC angemeckerten Dinge sind loesbar.
Die Medi selber ist schon seit Jahren auf den Markt, es geht (vorerst) nur um das Geraet mit dem die Nanotabletten "sicher" verabreicht werden koennen. Weitere Multiplikatoren waeren ARX-02/03/04 die in die gleiche Kerbe schlagen.
Soweit ich gesehen habe gab es gestern eine Reihe von Insiderkaeufen:
http://ir.acelrx.com/phoenix.zhtml?c=241441&p=irol-sec
Zeitrahmen: 6-12 Monate
--
!!Keine Meinung, Keine Handelsempfehlung!!
Die Aktie ist gestern um 41% auf bis $6.11 eingebrochen. Der Markt hat hier aber mMn ueberreagiert. Die im cc genannten und von der SEC angemeckerten Dinge sind loesbar.
Die Medi selber ist schon seit Jahren auf den Markt, es geht (vorerst) nur um das Geraet mit dem die Nanotabletten "sicher" verabreicht werden koennen. Weitere Multiplikatoren waeren ARX-02/03/04 die in die gleiche Kerbe schlagen.
Soweit ich gesehen habe gab es gestern eine Reihe von Insiderkaeufen:
http://ir.acelrx.com/phoenix.zhtml?c=241441&p=irol-sec
Zeitrahmen: 6-12 Monate
--
!!Keine Meinung, Keine Handelsempfehlung!!
Kursziele werden nur marhinal nach unten angepasst + die Insider, ein bißchen Geduld und Ende des Jahres mit hoher Wahrscheinlichkeit wieder über 10 USD.
AcelRx Pharmaceuticals Inc logoJefferies Group dropped their target price on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from $17.00 to $16.00 in a research report issued to clients and investors on Tuesday. Jefferies Group’s price target would indicate a potential upside of 148.06% from the company’s current price.
A number of other firms have also recently commented on ACRX. Analysts at Cowen and Company reiterated an “outperform” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, July 29th. They now have a $14.00 price target on the stock, down previously from $15.00. Separately, analysts at Piper Jaffray downgraded shares of AcelRx Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $8.00 price target on the stock, down previously from $14.00. Finally, analysts at JMP Securities cut their price target on shares of AcelRx Pharmaceuticals from $14.00 to $12.00 in a research note on Monday, July 28th. They now have an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.06.
quelle: http://www.wkrb13.com/markets/354336/acelrx-pharmaceuticals-…
AcelRx Pharmaceuticals Inc logoJefferies Group dropped their target price on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from $17.00 to $16.00 in a research report issued to clients and investors on Tuesday. Jefferies Group’s price target would indicate a potential upside of 148.06% from the company’s current price.
A number of other firms have also recently commented on ACRX. Analysts at Cowen and Company reiterated an “outperform” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, July 29th. They now have a $14.00 price target on the stock, down previously from $15.00. Separately, analysts at Piper Jaffray downgraded shares of AcelRx Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $8.00 price target on the stock, down previously from $14.00. Finally, analysts at JMP Securities cut their price target on shares of AcelRx Pharmaceuticals from $14.00 to $12.00 in a research note on Monday, July 28th. They now have an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.06.
quelle: http://www.wkrb13.com/markets/354336/acelrx-pharmaceuticals-…
An FDA Rejection Can Help Foster Confidence? The Compelling Case For AcelRx Pharmaceuticals
http://seekingalpha.com/article/2486815-an-fda-rejection-can…
http://seekingalpha.com/article/2486815-an-fda-rejection-can…
A Little Impatience And A Lot Of Skepticism Provides An Excellent Risk-Reward In AcelRx Pharmaceuticals
http://seekingalpha.com/article/2789515-a-little-impatience-…
http://seekingalpha.com/article/2789515-a-little-impatience-…
Heute Short squeeze vor der Präsentation in den Tagen?
http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-acelrxn…
http://news.acelrx.com/phoenix.zhtml?c=241441&p=irol-acelrxn…
Morgen erstmal 4.04usd das Ziel, evtl. kommt nennend das Gap Close 
Na wenn da heute nichts geht^^
Antwort auf Beitrag Nr.: 51.835.174 von Investment-Broker am 25.02.16 14:16:01Geht doch schon los!
Gruß aaahhh
Gruß aaahhh
Gibt ja auch News
http://seekingalpha.com/news/3138816-acelrx-pharmas-arxminus…
http://seekingalpha.com/news/3138816-acelrx-pharmas-arxminus…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,94 | |
| -2,71 | |
| -8,10 | |
| -1,02 | |
| -0,61 | |
| -0,24 | |
| -2,21 | |
| -0,63 | |
| -1,36 | |
| -0,47 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 228 | ||
| 96 | ||
| 90 | ||
| 76 | ||
| 53 | ||
| 49 | ||
| 48 | ||
| 44 | ||
| 42 | ||
| 33 |
AcelRx mit FDA Ende Juli?
